Iodine Deficiency Drug Market Seen Reaching $314.08B by 2030

The Business Research Company says the global iodine deficiency drug market is projected to grow at a 10.1% CAGR through 2030, reaching $314.08 billion. The forecast points to rising iodine deficiency, stronger preventive health habits, and expanding screening and supplementation programs as the main growth drivers.

Why it matters: - The market forecast points to rising demand for treatments tied to iodine deficiency, a condition linked to thyroid enlargement, hypothyroidism and developmental delays. - Faster growth in iodine supplementation and screening could affect public health programs, nutrition strategy and drug distribution in multiple regions. - The report also signals growing commercial opportunity around precision nutrition, digital monitoring and biofortified food development.

What happened: - The Business Research Company projected the global iodine deficiency drug market will grow from $194.28 billion in 2025 to $213.5 billion in 2026. - The company said the market is expected to reach $314.08 billion by 2030, representing a 10.1% CAGR during the forecast period. - The report was released from London on July 2, 2026. - More information is available in the full market report.

The details: - Historical growth was tied to widespread iodine deficiency in developing countries, limited access to iodized salt initiatives, rising thyroid disorders, low awareness about micronutrient nutrition and weak public health screening. - The market is being driven by expanded national iodine supplementation programs, preventive healthcare nutrition strategies, precision nutrition, personalized medicine, digital health monitoring and biofortified food development. - The report highlighted AI-based thyroid disorder diagnostics, digital iodine deficiency screening, cloud-supported surveillance platforms, smart supply chain tracking and precision medicine approaches as emerging trends. - Iodine deficiency drugs are designed to prevent or treat health problems caused by insufficient iodine and help support thyroid hormone synthesis and metabolic regulation. - The products are intended to reduce risk of goiter, hypothyroidism and developmental delays. - The report said insufficient iodine intake is rising as diets shift away from iodine-rich foods such as dairy products, iodized salt and bread. - The Iodine Global Network reported in April 2025 that the number of countries with insufficient iodine intake rose to 23 from 19 in 2022. - The International Food Information Council said in June 2024 that 54% of Americans followed a specific diet or eating pattern over the past year. - The same survey found interest in protein consumption rose from 59% in 2022 to 71% in 2024, and nearly half of consumers aimed to increase fresh food intake.

Between the lines: - The forecast suggests iodine deficiency is moving from a niche nutrition issue to a broader preventive-health market opportunity. - The emphasis on digital tools and personalized medicine shows the category is expanding beyond traditional supplements and into data-driven care. - Rising health consciousness may support demand, but the biggest upside likely depends on whether public health systems can scale screening and supplementation.

What's next: - North America held the largest share of the market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America and the Middle East and Africa. - The Business Research Company said its 2026 reports also include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel dashboards, market hotspot infographics and updated graphics and tables. - The company provided contact details for expert follow-up and said the report is available through its website.